The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...
The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback